Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell lines

Chen,Xin; Chen,Xin; Chen,Xin; Gu,Jingyao; Gu,Jingyao; Gu,Jingyao; Huang,Jiali; Huang,Jiali; Huang,Jiali; Wen,Kang; Wen,Kang; Wen,Kang; Zhang,Ge; Zhang,Ge; Zhang,Ge; Chen,Zhenyao; Chen,Zhenyao; Chen,Zhenyao; Wang,Zhaoxia; Wang,Zhaoxia; Wang,Zhaoxia

doi:10.3892/ijmm.2023.5305

Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell lines

Authors:
- Xin Chen
- Jingyao Gu
- Jiali Huang
- Kang Wen
- Ge Zhang
- Zhenyao Chen
- Zhaoxia Wang
View Affiliations

Affiliations: Cancer Medical Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China, Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, Jiangsu 210009, P.R. China, Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
Published online on: September 7, 2023 https://doi.org/10.3892/ijmm.2023.5305
Article Number: 102
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Drug resistance is an urgent problem to be solved in the treatment of non‑small‑cell lung cancer (NSCLC). Osimertinib is a third‑generation EGFR‑tyrosine kinase inhibitor, which can improve the efficacy and quality of life of patients; however, the inevitable resistance after long‑term use of osimertinib often leads to treatment failure. Cell lines are key tools for basic and preclinical studies. At present, few osimertinib‑resistant cell lines (HCC827‑OR and H1975‑OR) have been established. In the present study, osimertinib‑resistant cell lines were established by gradually increasing the drug concentration. Half‑maximal inhibitory concentration (IC50), cell morphology, whole exon sequencing, Cell Counting Kit‑8 assay, EdU staining and flow cytometry were used to evaluate the osimertinib‑resistant cell lines. Western blot analysis was used to detect the expression levels of key proteins involved in osimertinib resistance. The circular RNA (circRNA) expression profile was identified by RNA sequencing (RNA‑seq) analysis of HCC827, HCC827‑OR, H1975 and H1975‑OR cells. Subsequently, the biological roles of differentially expressed circRNAs were explored in in vitro studies. Osimertinib‑resistant cell lines were successfully established via treatment with an increasing concentration of osimertinib. Osimertinib IC50 and proliferation of resistant cells were much higher than those of sensitive cells. Notably, phosphorylated (p)‑AKT and p‑ERK were markedly activated in resistant cells, and the inhibitory effect of osimertinib on p‑AKT and p‑ERK was weaker in resistant cells than that in parental cells. RNA‑seq analysis identified differentially expressed circRNAs in HCC827, HCC827‑OR, H1975 and H1975‑OR cells. The most dysregulated circRNAs (circPDLIM5 and circPPP4R1) were selected for further functional study. Kyoto Encyclopedia of Genes and Genomes pathway analysis showed that the host genes of differentially expressed circRNAs were associated with ‘endocytosis’ and ‘regulation of autophagy’. In conclusion, the present study established osimertinib‑resistant cell lines and revealed that circRNAs may serve as a promising biomarker in NSCLC osimertinib resistance.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Testa U, Castelli G and Pelosi E: Lung cancers: Molecular characterization, clonal heterogeneity and evolution, and cancer stem cells. Cancers (Basel). 10:2482018. View Article : Google Scholar : PubMed/NCBI
3	Normanno N, Maiello MR, Chicchinelli N, Iannaccone A, Esposito C, De Cecio R, D'alessio A and De Luca A: Targeting the EGFR T790M mutation in non-small-cell lung cancer. Expert Opin Ther Targets. 21:159–165. 2017. View Article : Google Scholar
4	Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, et al: Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 382:41–50. 2020. View Article : Google Scholar
5	Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F and Ou SI: Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol. 16:740–763. 2021. View Article : Google Scholar
6	Park S and Ahn MJ: Osimertinib in central nervous system progressive EGFR-mutant lung cancer: Do we need to detect T790M? Ann Oncol. 31:15822020. View Article : Google Scholar : PubMed/NCBI
7	Nakatani K, Yamaoka T, Ohba M, Fujita KI, Arata S, Kusumoto S, Taki-Takemoto I, Kamei D, Iwai S, Tsurutani J and Ohmori T: KRAS and EGFR amplifications mediate resistance to rociletinib and osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR. Mol Cancer Ther. 18:112–126. 2019. View Article : Google Scholar
8	Nishiyama A, Takeuchi S, Adachi Y, Otani S, Tanimoto A, Sasaki M, Matsumoto S, Goto K and Yano S: MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib. Cancer Sci. 111:3813–3823. 2020. View Article : Google Scholar : PubMed/NCBI
9	Tian X, Wang R, Gu T, Ma F, Laster KV, Li X, Liu K, Lee MH and Dong Z: Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer. Mol Cancer. 21:1932022. View Article : Google Scholar : PubMed/NCBI
10	Booth L, West C, Moore RP, Von Hoff D and Dent P: GZ17-6.02 and pemetrexed interact to kill osimertinib-resistant NSCLC cells that express mutant ERBB1 proteins. Front Oncol. 11:7110432021. View Article : Google Scholar : PubMed/NCBI
11	Cao P, Li Y, Shi R, Yuan Y, Gong H, Zhu G, Zhang Z, Chen C, Zhang H, Liu M, et al: Combining EGFR-TKI with SAHA overcomes EGFR-TKI-acquired resistance by reducing the protective autophagy in non-small cell lung cancer. Front Chem. 10:8379872022. View Article : Google Scholar : PubMed/NCBI
12	Fu K, Xie F, Wang F and Fu L: Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. J Hematol Oncol. 15:1732022. View Article : Google Scholar : PubMed/NCBI
13	Ebbesen KK, Hansen TB and Kjems J: Insights into circular RNA biology. RNA Biol. 14:1035–1045. 2017. View Article : Google Scholar :
14	Huang W, Yang Y, Wu J, Niu Y, Yao Y, Zhang J, Huang X, Liang S, Chen R, Chen S and Guo L: Circular RNA cESRP1 sensitises small cell lung cancer cells to chemotherapy by sponging miR-93-5p to inhibit TGF-β signalling. Cell Death Differ. 27:1709–1727. 2020. View Article : Google Scholar
15	Wang C, Tan S, Li J, Liu WR, Peng Y and Li W: CircRNAs in lung cancer-biogenesis, function and clinical implication. Cancer Lett. 492:106–115. 2020. View Article : Google Scholar : PubMed/NCBI
16	Wang T, Liu Z, She Y, Deng J, Zhong Y, Zhao M, Li S, Xie D, Sun X, Hu X and Chen C: A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis. Cancer Lett. 520:321–331. 2021. View Article : Google Scholar : PubMed/NCBI
17	Zhang LX, Gao J, Long X, Zhang PF, Yang X, Zhu SQ, Pei X, Qiu BQ, Chen SW, Lu F, et al: The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis. Mol Cancer. 21:1102022. View Article : Google Scholar : PubMed/NCBI
18	Zhang PF, Pei X, Li KS, Jin LN, Wang F, Wu J and Zhang XM: Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells. Mol Cancer. 18:1792019. View Article : Google Scholar : PubMed/NCBI
19	Wen C, Xu G, He S, Huang Y, Shi J, Wu L and Zhou H: Screening circular RNAs related to acquired gefitinib resistance in non-small cell lung cancer cell lines. J Cancer. 11:3816–3826. 2020. View Article : Google Scholar : PubMed/NCBI
20	Chen T, Luo J, Gu Y, Huang J, Luo Q and Yang Y: Comprehensive analysis of circular RNA profiling in AZD9291-resistant non-small cell lung cancer cell lines. Thorac Cancer. 10:930–941. 2019. View Article : Google Scholar : PubMed/NCBI
21	Ma J, Qi G and Li L: A novel serum exosomes-based biomarker hsa_circ_0002130 facilitates osimertinib-resistance in non-small cell lung cancer by sponging miR-498. Onco Targets Ther. 13:5293–5307. 2020. View Article : Google Scholar : PubMed/NCBI
22	Pan J, Xing J, Yu H, Wang Z, Wang W and Pan Y: CircRBM33 promotes migration, invasion and mediates osimertinib resistance in non-small cell lung cancer cell line. Ann Transl Med. 11:2522023. View Article : Google Scholar : PubMed/NCBI
23	Tang ZH, Jiang XM, Guo X, Fong CM, Chen X and Lu JJ: Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line. Oncotarget. 7:81598–81610. 2016. View Article : Google Scholar : PubMed/NCBI
24	Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
25	Damgaard MV and Treebak JT: Protocol for qPCR analysis that corrects for cDNA amplification efficiency. STAR Protoc. 3:1015152022. View Article : Google Scholar : PubMed/NCBI
26	Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK: VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22:568–576. 2012. View Article : Google Scholar : PubMed/NCBI
27	Talevich E, Shain AH, Botton T and Bastian BC: CNVkit: Genome-wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput Biol. 12:e10048732016. View Article : Google Scholar : PubMed/NCBI
28	Zhang X, Maity TK, Ross KE, Qi Y, Cultraro CM, Bahta M, Pitts S, Keswani M, Gao S, Nguyen KDP, et al: Alterations in the global proteome and phosphoproteome in third generation EGFR TKI resistance reveal drug targets to circumvent resistance. Cancer Res. 81:3051–3066. 2021. View Article : Google Scholar : PubMed/NCBI
29	Birgisdottir ÅB and Johansen T: Autophagy and endocytosis-interconnections and interdependencies. J Cell Sci. 133:jcs2281142020. View Article : Google Scholar
30	Ganapathy AS, Saha K, Suchanec E, Singh V, Verma A, Yochum G, Koltun W, Nighot M, Ma T and Nighot P: AP2M1 mediates autophagy-induced CLDN2 (claudin 2) degradation through endocytosis and interaction with LC3 and reduces intestinal epithelial tight junction permeability. Autophagy. 18:2086–2103. 2022. View Article : Google Scholar :
31	Nnah IC, Wang B, Saqcena C, Weber GF, Bonder EM, Bagley D, De Cegli R, Napolitano G, Medina DL, Ballabio A and Dobrowolski R: TFEB-driven endocytosis coordinates MTORC1 signaling and autophagy. Autophagy. 15:151–164. 2019. View Article : Google Scholar
32	Yochum ZA, Cades J, Wang H, Chatterjee S, Simons BW, O'Brien JP, Khetarpal SK, Lemtiri-Chlieh G, Myers KV, Huang EH, et al: Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene. 38:656–670. 2019. View Article : Google Scholar
33	Yu HA, Schoenfeld AJ, Makhnin A, Kim R, Rizvi H, Tsui D, Falcon C, Houck‑Loomis B, Meng F, Yang JL, et al: Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial. JAMA Oncol. 6:1048–1054. 2020. View Article : Google Scholar : PubMed/NCBI
34	Tang ZH and Lu JJ: Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies. Cancer Lett. 420:242–246. 2018. View Article : Google Scholar : PubMed/NCBI
35	Chen Z, Chen Q, Cheng Z, Gu J, Feng W, Lei T, Huang J, Pu J, Chen X and Wang Z: Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1. Cell Death Dis. 11:8582020. View Article : Google Scholar : PubMed/NCBI
36	Verusingam ND, Chen YC, Lin HF, Liu CY, Lee MC, Lu KH, Cheong SK, Han-Kiat Ong A, Chiou SH and Wang ML: Generation of osimertinib-resistant cells from epidermal growth factor receptor L858R/T790M mutant non-small cell lung carcinoma cell line. J Chin Med Assoc. 84:248–254. 2021. View Article : Google Scholar
37	Kristensen LS, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB and Kjems J: The biogenesis, biology and characterization of circular RNAs. Nat Rev Genet. 20:675–691. 2019. View Article : Google Scholar : PubMed/NCBI
38	Kristensen LS, Jakobsen T, Hager H and Kjems J: The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 19:188–206. 2022. View Article : Google Scholar
39	Li R, Jiang J, Shi H, Qian H, Zhang X and Xu W: CircRNA: A rising star in gastric cancer. Cell Mol Life Sci. 77:1661–1680. 2020. View Article : Google Scholar
40	Zhang M, Bai X, Zeng X, Liu J, Liu F and Zhang Z: circRNA-miRNA-mRNA in breast cancer. Clin Chim Acta. 523:120–130. 2021. View Article : Google Scholar : PubMed/NCBI
41	Chen H, Liu S, Li M, Huang P and Li X: circ_0003418 inhibits tumorigenesis and cisplatin chemoresistance through Wnt/β-catenin pathway in hepatocellular carcinoma. Onco Targets Ther. 12:9539–9549. 2019. View Article : Google Scholar :
42	Zheng F and Xu R: CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis. Biomed Pharmacother. 124:1098282020. View Article : Google Scholar : PubMed/NCBI
43	Liu S, Jiang Z, Xiao P, Li X, Chen Y, Tang H, Chai Y, Liu Y, Zhu Z, Xie Q, et al: Hsa_circ_0005576 promotes osimertinib resistance through the miR‑512‑5p/IGF1R axis in lung adenocarcinoma cells. Cancer Sci. 113:79–90. 2022. View Article : Google Scholar
44	Dai C, Ma Z, Si J, An G, Zhang W, Li S and Ma Y: Hsa_circ_0007312 promotes third‑generation epidermal growth factor receptor‑tyrosine kinase inhibitor resistance through pyroptosis and apoptosis via the MiR‑764/MAPK1 axis in lung adenocarcinoma cells. J Cancer. 13:2798–2809. 2022. View Article : Google Scholar :
45	Ji Y, Zhao Q, Feng W, Peng Y, Hu B and Chen Q: N6-methyladenosine modification of CIRCKRT17 initiated by METTL3 promotes osimertinib resistance of lung adenocarcinoma by EIF4A3 to enhance YAP1 stability. Cancers (Basel). 14:55822022. View Article : Google Scholar : PubMed/NCBI
46	Lin Z, Niu Y, Wan A, Chen D, Liang H, Chen X, Sun L, Zhan S, Chen L, Cheng C, et al: RNA m⁶A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 39:e1031812020. View Article : Google Scholar
47	Luo Y, Zheng S, Wu Q, Wu J, Zhou R, Wang C, Wu Z, Rong X, Huang N, Sun L, et al: Long noncoding RNA (lncRNA) EIF3J-DT induces chemoresistance of gastric cancer via autophagy activation. Autophagy. 17:4083–4101. 2021. View Article : Google Scholar : PubMed/NCBI
48	Paquette M, El-Houjeiri L, C Zirden L, Puustinen P, Blanchette P, Jeong H, Dejgaard K, Siegel PM and Pause A: AMPK-dependent phosphorylation is required for transcriptional activation of TFEB and TFE3. Autophagy. 17:3957–3975. 2021. View Article : Google Scholar : PubMed/NCBI